Acrivon Therapeutics, Inc.(ACRV)Stock Analysis

ACRV Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Acrivon Therapeutics, Inc. (ACRV), a Healthcare sector company. ACRV is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Acrivon Therapeutics, Inc. reports net income of $-19.0M, free cash flow of $-20.6M. Top institutional holders of ACRV by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., Sands Capital Ventures,, WELLINGTON MANAGEMENT GROUP LLP, based on the most recent SEC filings. ACRV trades on the Nasdaq exchange and files with the SEC under CIK 1781174. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ACRV daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Acrivon Therapeutics, Inc. directly from SEC EDGAR.